KLOTHO THERAPEUTICS™

Since: 2016 San Diego, CA

KLOTHO Therapeutics (KTI) is a biotechnology company developing a patent-pending Klotho protein that has great potential to redefine society’s experience with aging.

Meet KLOTHO

This page is managed by our partners. The opinions expressed and content displayed are theirs, not ours, and they do not purport to reflect the opinions or views of Aspect Health or YourDNA.com. We make no claims to their accuracy.

Summary

Klotho Therapeutics, Inc., (KTI) is a privately held biotechnology company developing modified recombinant versions of the human protein Klotho that has shown great potential to delay diseases of aging and improve longevity. The company builds upon the $100+ million invested in Klotho related academic research that demonstrates how Klotho, a naturally occurring protein in humans and animals, can positively impact aging, cognition, kidney function, fibrosis, and cancer. KTI has worldwide patents pending on modified, recombinant Klotho proteins that can be readily manufactured using standard cell culture technology.

Powered by Froala Editor

Company Updates

Company Management

JAMES “JIM” PLANTE

Founder, Chairman & CEO

LinkedIn

K'Lene LeCompte

Business Officer

LinkedIn

Company Jobs